Kosnopfel C, Sinnberg T, Sauer B, et al. MAPK inhibitor resistant melanoma cells can be effectively targeted by inhibition of the p90 ribosomal S6 kinase. SMR 2017, abstract P01-9.
(Neo)adjuvant erlotinib plus cisplatine verbetert uitkomsten bij stadium III NSCLC
okt 2018 | Longoncologie